Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
McKesson
Dow
Johnson and Johnson
Express Scripts

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Litigation Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2014)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Orexo AB v. Actavis Elizabeth LLC (D. Del. 2014)

Docket   Start Trial Date Filed 2014-06-26
Court District Court, D. Delaware Date Terminated 2016-11-15
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand Defendant Referred To Sherry R. Fallon
Parties ACTAVIS ELIZABETH LLC; ACTAVIS INC.; OREXO AB; OREXO US INC.
Patents 6,761,910; 8,454,996; 8,470,361; 8,475,832; 8,512,747; 8,658,198; 8,940,330
Attorneys Anna Brook; David A. Bilson; Derek James Fahnestock; George C. Lombardi; Ivan M. Poullaos; Jack B. Blumenfeld; John C. Phillips , Jr.; Karl A. Leonard; Melinda K. Lackey; Michael K. Nutter; Regina S.E. Murphy; Tyler G. Johannes
Firms Barnes and Thornburg LLP; Morris, Nichols, Arsht & Tunnell; Phillips, Goldman, McLaughlin & Hall, P.A.
Link to Docket External link to docket
Small Molecule Drugs cited in Orexo AB v. Actavis Elizabeth LLC
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2015-10-06 127 disputed claim language of U.S. Patent Nos. 8,454,996 ("the '996 patent") and 8,940,330 ("…acceptable substances. 3 ('330 patent, 7:28-30; '996 patent, 4:41-43) 1 Found in claims 1 …1 and 2 of the '996 patent and in claims 1, 3-6, 10 of the '330 patent. 2 This construction is…agents .... " ('996 patent, abstract; 2:64-67) The '996 patent explains that "a bio/mucoadhesion… claim 1 of the '996 patent. 5 Found in claim 1 of the '330 patent. External link to document
2016-11-15 228 alleging infringement of U.S. Patent Nos. 8,454,996 ("the '996 patent") and 8,940,330 ("…'996 patent. 38 Claim 2 of the '996 patent. 39Claim 1 of the '330 patent. Actavis … 2. The '996 patent The '996 patent, titled "Pharmaceutical Composition… with carrier particles. ('996 patent, 12: 18-43) The patent states that using "ordered mixtures…and useful results." ('996 patent, 3:56-61) The patent explains that "[a] variety of polymers External link to document
2014-06-26 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,454,996 B2; 8,470,361 B2; 8,658,198… 15 November 2016 1:14-cv-00829 830 Patent Defendant District Court, D. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKinsey
Mallinckrodt
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.